---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-009487"
form_type: "8-K"
ticker: "SCYX"
cik: "0001178253"
company_name: "SCYNEXIS INC"
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-26T23:50:23.312305+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# SCYNEXIS receives $5M third tranche from Hercules/SVB Term Loan after CANDLE milestone

## Summary
- On March 9, 2022, SCYNEXIS drew $5M under its existing $60M Term Loan with Hercules/SVB.
- The tranche was triggered by positive Phase 3 CANDLE study results for ibrexafungerp.
- Prior draws: $20M at closing (May 2021), $10M on FDA approval (June 2021).
- Total drawn now $35M; remaining tranches subject to conditions.
- Loan facility provided by Hercules Capital and Silicon Valley Bank.

## SEC filing metadata
- accession: 0001564590-22-009487
- form_type: 8-K
- ticker: SCYX
- cik: 0001178253
- company_name: SCYNEXIS INC
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178253/000156459022009487/0001564590-22-009487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178253/000156459022009487/scyx-8k_20220309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-009487
- JSON: https://secwatch.observer/filing/0001564590-22-009487.json
- Plain text: https://secwatch.observer/filing/0001564590-22-009487.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.